French premarket delay plan - will it see the light of day?
This article was originally published in Clinica
Executive Summary
France has finally published the details of its plan that entails delayed market entry for some high-risk devices. The government has notified the European Commission and European Union member states about the range of products that will be subject to a requirement that will effectively mean a three-month delay for manufacturers. However, the plan will be found to be illegal on two counts, Paris-based consultant John McLoughlin told the Medical Device Technology European Conference in Paris last week.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.